|Bid||0.00 x 20000|
|Ask||0.00 x 9000|
|Day's range||154.05 - 156.00|
|52-week range||120.65 - 172.95|
|PE ratio (TTM)||16.51|
|Dividend & yield||N/A (N/A)|
|1y target est||N/A|
Credit Suisse's Alethia Young and her team take a look at the biotech sector ahead of earnings, writing that they expect large-cap companies' strength to continue through the end of the year. Young writes that she expects most companies to be either in-line or above consensus estimates when they report third-quarter results, as large cap biotechs have been strong heading into t he third quarter. Among stocks where she has the most conviction in the quarter, she thinks that Biogen (BIIB) can beat expectations thanks to Spinraza (it's spinal muscular atrophy drug) trends in the U.S. She writes that she thinks investors should expect a "solid" quarter from Bioverativ (BIVV) as well, and will also be focusing on sales from Regeneron's (REGN) Dupixent and Gilead's (GILD) HCV franchise.
Continuity efforts at Amgen's Puerto Rico drug manufacturing plant reveal the dedication of the island's workers in the pharmaceutical and medical device industries.
EVENITY (romosozumab) is a monoclonal antibody under investigation that acts by inhibiting the activity of sclerostin.
Aimovig is the only biologic product under investigation that has been designed specifically to prevent a migraine by inhibiting the CGRP (calcitonin gene-related peptide) receptor.
Gabelli & Co. We reiterate a Buy rating on Regeneron Pharmaceuticals with an estimated 2018 private market value of $554 a share. On Oct. 5, Regeneron (REGN) announced that the appeals court has removed the permanent injunction on Praluent. The injunction was issued in January to block sales of Praluent, after a federal jury ruled against Regeneron in patent litigation and declared two of Amgen’s (AMGN) patents linked to PCSK9 in March 2016 valid.
In September 2017, Amgen and Allergan presented results from the Phase 3 trial, which evaluated the safety and efficacy of ABP 980, a proposed biosimilar to Herceptin.
Of the 24 analysts tracking Amgen (AMGN) in October 2017, ~42% of the analysts recommended a “buy” rating, and the rest suggested a ”hold.” On October 5, Amgen had a consensus 12-month target price of ...
The Food and Drug Administration on Friday warned that U.S. drug shortages are possible because power outages in Puerto Rico have stopped or limited production at many medicine factories there.
A U.S. federal appeals court said Regeneron Pharmaceuticals and partner Sanofi can continue selling their cholesterol drug, dealing a blow to rival Amgen, which had accused the companies of violating its ...
Shares of Amgen (AMGN) are sliding this morning after a judge ruled that Regeneron Pharmaceuticals' (REGN) Praluent can stay on the market for the time being. The ruling was made in an ongoing patent battle between Amgen and Regeneron and its partner Sanofi (SNY). The Court is allowing for REGN's Praluent to stay on the market for the time being on the basis the that earlier proceeding in district court was conducted in error.
CytomX Therapeutics Inc. roared 35% higher in after-hours trading Tuesday to prices that would be record highs after announcing a partnership with biotech giant Amgen Inc. The companies will collaborate ...
Shares of AbbVie (ABBV) have soared this year --and there are plenty of reasons for investor optimism. Humira for one, looks less exposed to competition, while AbbVie's pipeline could also produce some winners. In fact, the news has been so good that AbbVie was upgraded to Outperform from Market Perform by Leerink's Geoffrey Porges and Bradley Canino despite the fact that the stock has gained more than 40% so far this year.
Puerto Rico's island-wide power outage will mean a surge in insurance claims for lost business income that will increase the already high cost of damage caused by Hurricane Maria, likely tipping some big reinsurers into the red this year, according to industry experts. Claims from Maria, on top of two other major Caribbean hurricanes this season, could push total global catastrophe losses for the year as high as $190 billion, according to some estimates, which would make it the most costly year on record for the insurance and reinsurance industries.
AbbVie was the S&P 500's second-highest gainer on September 28, 2017. On September 28, AbbVie rose 5% and closed the day at $88.96.
Drugmakers AbbVie and Amgen reached a patent-dispute settlement requiring Amgen to wait until 2023 to start selling a lower-priced copy of the world’s top-selling drug, AbbVie’s arthritis treatment Humira, ...
It has been a major overhang for AbbVie’s (ABBV) stock price. Amgen (AMGN) and AbbVie have come to terms over the launch of a so-called biosimilar rival to the blockbuster autoimmune medication Humira. Amgen will delay its launch of Amjevita in the U.S. until the end of Jan. 2023, even though the drug received FDA approval roughly a year ago.
A new kind of injectable biotech treatment for severe asthma from AstraZeneca (NYSE: AZN - news) and Amgen (Swiss: AMGN-USD.SW - news) promises to help a much broader range of patients than existing medicines like GlaxoSmithKline’s Nucala. Findings from a mid-stage clinical trial involving 584 patients showed on Wednesday the experimental drug tezepelumab reduced the annual rate of serious asthma attacks, known as exacerbations, by between 61 and 71 percent, depending on dose. "Tezepelumab appears to be the broadest and most promising biologic for the treatment of persistent uncontrolled asthma to date," Elisabeth Bel of Amsterdam's Academic Medical Center wrote in an editorial in the New England Journal of Medicine.
A new kind of injectable biotech treatment for severe asthma from AstraZeneca (NYSE: AZN - news) and Amgen (Swiss: AMGN-USD.SW - news) promises to help a much broader range of patients than existing medicines like GlaxoSmithKline’s Nucala. Findings from a mid-stage clinical trial involving 584 patients showed on Wednesday the experimental drug tezepelumab reduced the annual rate of serious asthma attacks, known as exacerbations, by between 61 and 71 percent, depending on dose. The results could put the first-in-class injection in a strong position in a competitive market as it heads into final-stage Phase III tests later this year or early next.
A global stock market index hovered near record highs on Friday, wrapping up a week when many of the world's biggest economies either raised interest rates or signaled they might do so, underlining confidence about economic growth and inflation. The U.S. dollar fell, continuing its slide in the wake of the Federal Reserve's decision on Wednesday to boost interest rates but maintain a gradual pace of hikes this year.
The Dow came within one point of 20,000 for the first time ever on Friday, fueled by a rise in Apple (NasdaqGS: AAPL - news) and extending a two-month rally fueled by optimism that President-elect Donald Trump's policies will bolster the economy. Apple rose 1.3 percent, helping all three major indexes, after Canada's Competition Bureau said it did not find sufficient evidence iPhone maker had engaged in anti-competitive conduct, closing a two-year investigation into the company. U.S. stocks have risen sharply since Trump won the U.S. election in November and while Friday's additional gains suggested the rally is not yet over, some investors have grown cautious.